BRPI0513677A - derivados de pirrol com agentes farmacêuticos - Google Patents
derivados de pirrol com agentes farmacêuticosInfo
- Publication number
- BRPI0513677A BRPI0513677A BRPI0513677-6A BRPI0513677A BRPI0513677A BR PI0513677 A BRPI0513677 A BR PI0513677A BR PI0513677 A BRPI0513677 A BR PI0513677A BR PI0513677 A BRPI0513677 A BR PI0513677A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical agents
- receptor activity
- pyrrol derivatives
- derivatives
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59246904P | 2004-07-30 | 2004-07-30 | |
US59243904P | 2004-07-30 | 2004-07-30 | |
US60/592,439 | 2004-07-30 | ||
US60/592,469 | 2004-07-30 | ||
PCT/US2005/026916 WO2006012642A2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0513677A true BRPI0513677A (pt) | 2007-11-27 |
BRPI0513677B1 BRPI0513677B1 (pt) | 2020-12-01 |
BRPI0513677B8 BRPI0513677B8 (pt) | 2021-05-25 |
Family
ID=35786783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513677A BRPI0513677B8 (pt) | 2004-07-30 | 2005-07-30 | derivados de pirrol como agentes farmacêuticos |
Country Status (21)
Country | Link |
---|---|
US (2) | US8026237B2 (pt) |
EP (1) | EP1773768B8 (pt) |
JP (2) | JP4703649B2 (pt) |
KR (1) | KR101155288B1 (pt) |
AU (1) | AU2005266890C1 (pt) |
BR (1) | BRPI0513677B8 (pt) |
CA (1) | CA2573426C (pt) |
CY (1) | CY1120922T1 (pt) |
DK (1) | DK1773768T3 (pt) |
ES (1) | ES2697524T3 (pt) |
HU (1) | HUE041596T2 (pt) |
IL (1) | IL180630A (pt) |
LT (1) | LT1773768T (pt) |
NO (1) | NO344324B1 (pt) |
NZ (1) | NZ552632A (pt) |
PL (1) | PL1773768T3 (pt) |
PT (1) | PT1773768T (pt) |
RU (1) | RU2470916C2 (pt) |
SG (1) | SG155188A1 (pt) |
SI (1) | SI1773768T1 (pt) |
WO (1) | WO2006012642A2 (pt) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2567135T3 (es) * | 2003-08-29 | 2016-04-20 | The Brigham And Women's Hospital, Inc. | Derivados de hidantoína como inhibidores de necrosis celular |
SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
DE10354060A1 (de) * | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | Pyrrolderivate |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
JP4703649B2 (ja) * | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | 薬学的因子としてのピロール誘導体 |
MX2007003105A (es) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
CN101142172A (zh) | 2005-01-05 | 2008-03-12 | 艾博特公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
CA2594098C (en) | 2005-01-05 | 2014-04-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
AU2006205220B2 (en) * | 2005-01-10 | 2012-09-13 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
CA2667966C (en) | 2006-10-31 | 2011-08-02 | Pfizer Products Inc. | Pyrazoline compounds as mineralocorticoid receptor antagonists |
CN101679243B (zh) | 2007-04-09 | 2012-09-26 | 第一三共株式会社 | 吡咯衍生物的阻转异构体 |
EP2192838A4 (en) * | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
JP2010536871A (ja) * | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | スフィンゴシン−1−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物 |
MX2010002712A (es) | 2007-09-10 | 2010-06-09 | Calcimedica Inc | Compuestos que modulan calcio intracelular. |
US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
KR20100119582A (ko) * | 2008-03-31 | 2010-11-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 수니티닙 및 이의 염을 제조하는 방법 |
GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
EP2318007B1 (en) | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
DK2315591T3 (en) | 2008-08-15 | 2016-06-06 | Nivalis Therapeutics Inc | NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents |
US8642628B2 (en) | 2008-08-15 | 2014-02-04 | N30 Pharmaceuticals, Inc. | Pyrrole inhibitors of S-nitrosoglutathione reductase |
BRPI0917719A2 (pt) | 2008-08-27 | 2019-11-19 | Calcimedica Inc | compostos que modulam cálcio intracelular |
US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
BRPI0920459B1 (pt) * | 2008-10-08 | 2021-12-14 | Exelixis, Inc | Compostos antagonistas de receptor de mineralocorticoide, composição farmacêutica e método in vitro de inibição da atividade do receptor de mineralocorticoide |
AU2009302375B2 (en) * | 2008-10-08 | 2015-03-26 | Exelixis, Inc. | 1-phenylpyrrole compounds |
BRPI0923126A2 (pt) | 2008-12-23 | 2021-09-08 | President And Fellows Of Harvard College | Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose |
WO2010107476A1 (en) * | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
JP5620979B2 (ja) * | 2009-05-05 | 2014-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | P38キナーゼ阻害剤 |
EP2253617A1 (de) * | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Halogen-substituierte Verbindungen als Pestizide |
US8669259B2 (en) | 2009-08-26 | 2014-03-11 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
EP2477982A4 (en) * | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
TWI532725B (zh) * | 2010-01-26 | 2016-05-11 | 賽諾菲阿凡提斯公司 | 經氧取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途 |
US8957052B2 (en) | 2010-05-10 | 2015-02-17 | Universite Paris Descartes | Methods and compositions for the treatment of fluid accumulation in and/or under the retina |
EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US20140113898A1 (en) * | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
US9815851B2 (en) | 2011-12-02 | 2017-11-14 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
NZ704752A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
JP2016514693A (ja) | 2013-03-15 | 2016-05-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハイブリッド型ネクロトーシス阻害剤 |
ES2640063T3 (es) | 2013-04-03 | 2017-10-31 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
HUE041725T2 (hu) | 2013-04-10 | 2019-05-28 | Daiichi Sankyo Co Ltd | (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
MX366787B (es) | 2013-05-17 | 2019-07-23 | Janssen Sciences Ireland Uc | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. |
WO2015012205A1 (ja) | 2013-07-23 | 2015-01-29 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
SG11201600522UA (en) | 2013-07-25 | 2016-02-26 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
HUE037007T2 (hu) | 2013-08-27 | 2018-08-28 | Daiichi Sankyo Co Ltd | Eljárás pirrol származék elõállítására és annak intermediere |
US9567299B2 (en) | 2013-10-23 | 2017-02-14 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2015083130A1 (en) * | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
AP2016009257A0 (en) | 2014-02-06 | 2016-06-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
TW201632516A (zh) | 2014-12-11 | 2016-09-16 | 哈佛大學校長及研究員協會 | 細胞壞死抑制劑與相關方法 |
BR112017015788B1 (pt) * | 2015-01-26 | 2023-05-16 | Daiichi Sankyo Company, Limited | Composição sólida, e, método de fabricação para uma composição sólida |
WO2016172496A1 (en) | 2015-04-23 | 2016-10-27 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
TWI623316B (zh) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
EP3423452A4 (en) * | 2016-03-01 | 2019-10-30 | University of Maryland, Baltimore | INHIBITORS OF THE WNT SIGNALING PATHWAY FOR THE TREATMENT OF DISEASES |
JP6934859B2 (ja) | 2016-03-24 | 2021-09-15 | 第一三共株式会社 | 腎疾患の治療のための医薬 |
MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
CN110022871A (zh) | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品 |
HRP20231369T1 (hr) | 2016-10-26 | 2024-02-16 | Constellation Pharmaceuticals, Inc. | Inhibitori lsd1 i njihova medicinska upotreba |
WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
CR20200378A (es) | 2018-03-14 | 2021-01-08 | Janssen Sciences Ireland Unlimited Co | Régimen posológico del modulador del emsalblaje de la cápside |
WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
CA3132554A1 (en) | 2019-05-06 | 2020-11-12 | Bart Rudolf Romanie Kesteleyn | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
CN112707854B (zh) | 2019-10-25 | 2022-03-15 | 年衍药业(珠海)有限公司 | 吡咯酰胺类化合物及其用途 |
RU2738405C1 (ru) * | 2020-05-26 | 2020-12-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | АМИД (Е)-2-АМИНО-4-ОКСО-5-(2-ОКСО-2-ФЕНИЛЭТИЛИДЕН)-1-(3-ЭТОКСИКАРБОНИЛ)-4,5,6-7-ТЕТРАГИДРОБЕНЗО[b]ТИОФЕН-2-ИЛ)4,5-ДИГИДРО-1Н-ПИРРОЛ-3-КАРБОНОВОЙ КИСЛОТЫ, ОБЛАДАЮЩИЙ ПРОТИВОМИКРОБНОЙ АКТИВНОСТЬЮ |
CN115246785B (zh) | 2021-04-26 | 2024-03-26 | 年衍药业(珠海)有限公司 | 吡咯酰胺化合物的制备方法 |
CN114456098A (zh) * | 2022-01-19 | 2022-05-10 | 大连理工大学 | 糖尿病肾病药物艾莎利酮的制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981000108A1 (en) * | 1979-06-28 | 1981-01-22 | Ciba Geigy Ag | Stabilizers for chlorinated thermoplast |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
JPH07116139B2 (ja) | 1986-06-09 | 1995-12-13 | 三菱化学株式会社 | ラクタム類の製造方法 |
DE3717068A1 (de) * | 1987-05-21 | 1988-12-08 | Basf Ag | 4-substituierte 10-cyanmethylen-pyrrolo(4,3-e)-benzo-azepine |
JPH04145078A (ja) * | 1990-10-04 | 1992-05-19 | Hokko Chem Ind Co Ltd | ピロールジカルボン酸誘導体および除草剤 |
JPH10251258A (ja) * | 1997-03-14 | 1998-09-22 | Suntory Ltd | ピロロアゼピン系化合物 |
DE19719585A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
RU2204390C2 (ru) * | 1998-01-14 | 2003-05-20 | Ниппон Синяку Ко., Лтд. | Активаторы калиевых каналов |
AU2960599A (en) * | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
GB9817548D0 (en) * | 1998-08-12 | 1998-10-07 | Novartis Ag | Organic compounds |
PL347591A1 (en) * | 1998-11-09 | 2002-04-08 | Gastrin and cholecystokinin receptor ligands | |
ATE286026T1 (de) * | 1999-02-10 | 2005-01-15 | Mitsubishi Pharma Corp | Amid-derivate und deren medizinische verwendung |
MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
PL367417A1 (en) * | 2001-07-19 | 2005-02-21 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US6987123B2 (en) * | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
DE60131967D1 (de) * | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
WO2003015777A1 (en) * | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
US20070010562A1 (en) * | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
US20040267028A1 (en) * | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
DE10148328A1 (de) | 2001-09-29 | 2003-04-10 | Bayerische Motoren Werke Ag | Verfahren zum Positionieren eines Kraftfahrzeug-Lenkrads |
US7078430B2 (en) * | 2002-07-08 | 2006-07-18 | Ranbaxy Laboratories Limited | HMG CoA-reductase inhibitors |
US7186716B2 (en) * | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
EP1398029A1 (en) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
CN1485072A (zh) | 2002-09-28 | 2004-03-31 | 治疗前列腺疾病的薏苡仁油软胶囊及其应用 | |
US20040102511A1 (en) * | 2002-11-21 | 2004-05-27 | Jitendra Sattigeri | Substituted pyrrole derivatives |
GB0230088D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
DE60330392D1 (de) * | 2003-01-02 | 2010-01-14 | Hoffmann La Roche | Cb 1 rezeptor inversagonisten |
DE60322114D1 (de) * | 2003-01-02 | 2008-08-21 | Hoffmann La Roche | Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors |
JP4703649B2 (ja) * | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | 薬学的因子としてのピロール誘導体 |
-
2005
- 2005-07-30 JP JP2007523832A patent/JP4703649B2/ja active Active
- 2005-07-30 BR BRPI0513677A patent/BRPI0513677B8/pt active IP Right Grant
- 2005-07-30 NZ NZ552632A patent/NZ552632A/en unknown
- 2005-07-30 HU HUE05803281A patent/HUE041596T2/hu unknown
- 2005-07-30 SG SG200905207-7A patent/SG155188A1/en unknown
- 2005-07-30 WO PCT/US2005/026916 patent/WO2006012642A2/en active Application Filing
- 2005-07-30 US US11/572,962 patent/US8026237B2/en active Active
- 2005-07-30 AU AU2005266890A patent/AU2005266890C1/en active Active
- 2005-07-30 EP EP05803281.4A patent/EP1773768B8/en active Active
- 2005-07-30 CA CA2573426A patent/CA2573426C/en active Active
- 2005-07-30 PL PL05803281T patent/PL1773768T3/pl unknown
- 2005-07-30 ES ES05803281T patent/ES2697524T3/es active Active
- 2005-07-30 LT LTEP05803281.4T patent/LT1773768T/lt unknown
- 2005-07-30 KR KR1020077004302A patent/KR101155288B1/ko active IP Right Grant
- 2005-07-30 SI SI200532237T patent/SI1773768T1/sl unknown
- 2005-07-30 DK DK05803281.4T patent/DK1773768T3/en active
- 2005-07-30 PT PT05803281T patent/PT1773768T/pt unknown
- 2005-07-30 RU RU2007107388/04A patent/RU2470916C2/ru active
-
2007
- 2007-01-10 IL IL180630A patent/IL180630A/en active IP Right Grant
- 2007-02-16 NO NO20070910A patent/NO344324B1/no unknown
-
2010
- 2010-01-15 JP JP2010007511A patent/JP2010077166A/ja not_active Withdrawn
-
2011
- 2011-08-22 US US13/214,665 patent/US8367667B2/en active Active
-
2018
- 2018-11-21 CY CY181101235T patent/CY1120922T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513677A (pt) | derivados de pirrol com agentes farmacêuticos | |
BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
BRPI0514269A (pt) | compostos heterocìclicos como agentes farmacêuticos | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
ATE547420T1 (de) | Azepinoindol und pyridoindolderivate als pharmazeutische mittel | |
EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
ATE534293T1 (de) | Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren | |
BRPI0417771A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóides | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
CR9078A (es) | Derivado de bencimidazol ariloxi-sustituidos | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
BRPI0506888A (pt) | composições de suplemento lìquido compreendendo um ou mais medicamentos | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
BRPI0507626A (pt) | compostos e composiçoes como moduladores de lxr | |
BRPI0412130A (pt) | compostos tetracìclicos como inibidores de c-met | |
TR200703092A1 (tr) | Flurbiprofen ve kas gevşetici kombinasyonları | |
BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: DESCONHECIDA A PETICAO DE ALTERACAO DE SEDE NO 020070102811/RJ DE 26/07/2007, POR NAO TRATAR-SE DE ALTERACAO DE SEDE DO TITULAR DO PEDIDO. |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: REFERENTE A RPI NO 2049 DE 13/04/2010. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |